Guohua Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Guohua Wang has a total of 316 co-authors. Here are the top co-authors by number of shared publications:
- Zheng-Lin Jiang
Nantong University
17 shared publications Xia Li
Nantong University
13 shared publicationsLisha Ye
Department of Neurophysiology and Neuropharmacology, Institute of Special Environmental Medicine and Co-innovation Center of Neuroregeneration, Nantong University, Nantong, China
10 shared publications- Qian-Qian Luo
Department of Neurophysiology and Neuropharmacology, Institute of Special Environmental Medicine and Co‐innovation Center of Neuroregeneration Nantong University Nantong Jiangsu China
10 shared publications Qianqian Luo
Department of Medicine, Henan Vocational College of Nursing, Anyang, Henan, China
8 shared publications- Jun Chen
Geriatric Research, Education and Clinical Center, Veterans Affairs Pittsburgh Health Care System, PA (J.L., S.H., W.Z., W.-C.W., F.Z., Q.Y., H.P., X.H., Y.S., J.C.).
7 shared publications
Latest Publications
- Open Access
- 13 November 2026
- Published by JMIR Publications Inc. in Journal of Medical Internet Research
- Vol. 28, e108001
A Fine-Tuned Large Language Model Workflow to Support Risk of Bias Assessment: Development, External Validation, and Reviewer Verification Study
Background: Given that randomized controlled trials (RCTs) are the gold standard for effectiveness research, assessing their risk of bias (RoB) becomes an indispensable step in systematic reviews. Yet this task remains time-consuming and prone to reviewer subjectivity. While large language models may accelerate the process, they lack transparent, traceable judgments linked to trial reports. Objective: To bridge methodological gaps and improve both efficiency and consistency, this study developed and externally validated TRoB-1, a fine-tuned open-weight large language model workflow for RoB assessment of RCTs. Methods: TRoB-1 was developed specifically for the Cochrane risk of bias tool version 1 (RoB 1), which is the most widely adopted instrument for critical appraisal of RCTs. The workflow generates preliminary judgments and supporting quotations from reviewer-selected passages for the target RoB domains. The workflow was built on 2-stage supervised fine-tuning of Gemma 2-9B-Instruct using 4-bit quantized low-rank adaptation. The training set comprised 4321 RoB records extracted from systematic reviews of chronic obstructive pulmonary disease, diabetes, and hypertension. The validation set consisted of 161 records from recently published RCTs covering a broader disease area. The reference standard was established by 2 independent reviewers. Two clinicians blinded to the reference standard verified TRoB-1-assisted assessments through a locally hosted web interface. Using the same reference standard, the performance of TRoB-1 raw outputs was compared with that of the Gemma 2 base workflow, and clinician-verified outputs were compared with raw TRoB-1 outputs. Results: TRoB-1 successfully generated structured outputs for all 161 validation records. In independent clinician-assisted assessments using the same workflow, raw TRoB-1 accuracy ranged from 73.3% (n=118) to 73.9% (n=119), compared with 52.2% (n=84) to 60.2% (n=97) for the Gemma 2 base model. After verification, accuracy ranged from 82.0% (n=132) to 84.5% (n=136) and macro- F 1 from 0.709 to 0.776. Accuracy remained higher for raw TRoB-1 after excluding invalid base-model outputs, and verification did not change any correct judgment to an incorrect one. Clinician 1 corrected 13 initially incorrect judgments and clinician 2 corrected 18. The F 1 -score for judgments of high-RoB increased from 0.600 to 0.784 for clinician 1 and from 0.571 to 0.821 for clinician 2. Conclusions: TRoB-1 combined task-specific fine-tuning, evidence-linked outputs, and clinician verification in a transparent workflow for reviewer-supported RoB assessment. The TRoB-1 web interface provides a practical platform for integrating RoB into evidence synthesis, particularly for living systematic reviews where timely updates are critical.
- 13 November 2026
- Published by JMIR Publications Inc. in Journal of Medical Internet Research
- Vol. 28, e108001
Open AccessA Fine-Tuned Large Language Model Workflow to Support Risk of Bias Assessment: Development, External Validation, and Reviewer Verification Study
Background: Given that randomized controlled trials (RCTs) are the gold standard for effectiveness research, assessing their risk of bias (RoB) becomes an indispensable step in systematic reviews. Yet this task remains time-consuming and prone to reviewer subjectivity. While large language models may accelerate the process, they lack transparent, traceable judgments linked to trial reports. Objective: To bridge methodological gaps and improve both efficiency and consistency, this study developed and externally validated TRoB-1, a fine-tuned open-weight large language model workflow for RoB assessment of RCTs. Methods: TRoB-1 was developed specifically for the Cochrane risk of bias tool version 1 (RoB 1), which is the most widely adopted instrument for critical appraisal of RCTs. The workflow generates preliminary judgments and supporting quotations from reviewer-selected passages for the target RoB domains. The workflow was built on 2-stage supervised fine-tuning of Gemma 2-9B-Instruct using 4-bit quantized low-rank adaptation. The training set comprised 4321 RoB records extracted from systematic reviews of chronic obstructive pulmonary disease, diabetes, and hypertension. The validation set consisted of 161 records from recently published RCTs covering a broader disease area. The reference standard was established by 2 independent reviewers. Two clinicians blinded to the reference standard verified TRoB-1-assisted assessments through a locally hosted web interface. Using the same reference standard, the performance of TRoB-1 raw outputs was compared with that of the Gemma 2 base workflow, and clinician-verified outputs were compared with raw TRoB-1 outputs. Results: TRoB-1 successfully generated structured outputs for all 161 validation records. In independent clinician-assisted assessments using the same workflow, raw TRoB-1 accuracy ranged from 73.3% (n=118) to 73.9% (n=119), compared with 52.2% (n=84) to 60.2% (n=97) for the Gemma 2 base model. After verification, accuracy ranged from 82.0% (n=132) to 84.5% (n=136) and macro- F 1 from 0.709 to 0.776. Accuracy remained higher for raw TRoB-1 after excluding invalid base-model outputs, and verification did not change any correct judgment to an incorrect one. Clinician 1 corrected 13 initially incorrect judgments and clinician 2 corrected 18. The F 1 -score for judgments of high-RoB increased from 0.600 to 0.784 for clinician 1 and from 0.571 to 0.821 for clinician 2. Conclusions: TRoB-1 combined task-specific fine-tuning, evidence-linked outputs, and clinician verification in a transparent workflow for reviewer-supported RoB assessment. The TRoB-1 web interface provides a practical platform for integrating RoB into evidence synthesis, particularly for living systematic reviews where timely updates are critical.
- Open Access
- 12 November 2026
- Published by Oxford University Press (OUP) in European Heart Journal Open
Chronic kidney disease and long-term risk of cerebrovascular vulnerability
Aims: Chronic kidney disease (CKD) is associated with increased stroke risk, but its relationship with early-onset stroke, preclinical brain alterations, and circulating molecular signatures remains incompletely characterized. Purpose: To investigate CKD-associated cerebrovascular vulnerability across clinical, neuroimaging, and proteomic perspectives. Methods and results: This population-based cohort study included 381,886 participants with available kidney function, albuminuria, and follow-up data. Cox proportional hazards models were used to evaluate the associations of CKD status, CKD stage, and kidney risk categories with incident stroke and early-onset stroke. CKD was associated with increased risks of overall stroke (HR 1.61, 95% CI 1.50-1.73) and early-onset stroke (HR 1.89, 95% CI 1.62-2.22), with risk increasing across CKD severity, lower eGFR, higher uACR, and higher kidney risk categories. Baseline CKD was also associated with greater white matter lesion burden, lower brain and grey matter volumes, and reduced ASL-derived cerebral blood flow before clinically overt stroke. Proteomic analyses identified five candidate proteins associated with stroke among participants with CKD. Of these, WFDC2 yielded the highest AUCs for 3- and 5-year stroke prediction when added individually to traditional risk factors. The addition of WFDC2 and HAVCR1 to a model containing traditional risk factors, eGFR, and uACR further increased the AUCs from 0.823 to 0.843 and from 0.792 to 0.816, respectively. Conclusion: CKD is associated with earlier stroke occurrence, preclinical structural and functional brain alterations, and circulating protein signatures related to stroke risk. WFDC2 may help refine stroke risk stratification in individuals with CKD.
- 12 November 2026
- Published by Oxford University Press (OUP) in European Heart Journal Open
Open AccessChronic kidney disease and long-term risk of cerebrovascular vulnerability
Aims: Chronic kidney disease (CKD) is associated with increased stroke risk, but its relationship with early-onset stroke, preclinical brain alterations, and circulating molecular signatures remains incompletely characterized. Purpose: To investigate CKD-associated cerebrovascular vulnerability across clinical, neuroimaging, and proteomic perspectives. Methods and results: This population-based cohort study included 381,886 participants with available kidney function, albuminuria, and follow-up data. Cox proportional hazards models were used to evaluate the associations of CKD status, CKD stage, and kidney risk categories with incident stroke and early-onset stroke. CKD was associated with increased risks of overall stroke (HR 1.61, 95% CI 1.50-1.73) and early-onset stroke (HR 1.89, 95% CI 1.62-2.22), with risk increasing across CKD severity, lower eGFR, higher uACR, and higher kidney risk categories. Baseline CKD was also associated with greater white matter lesion burden, lower brain and grey matter volumes, and reduced ASL-derived cerebral blood flow before clinically overt stroke. Proteomic analyses identified five candidate proteins associated with stroke among participants with CKD. Of these, WFDC2 yielded the highest AUCs for 3- and 5-year stroke prediction when added individually to traditional risk factors. The addition of WFDC2 and HAVCR1 to a model containing traditional risk factors, eGFR, and uACR further increased the AUCs from 0.823 to 0.843 and from 0.792 to 0.816, respectively. Conclusion: CKD is associated with earlier stroke occurrence, preclinical structural and functional brain alterations, and circulating protein signatures related to stroke risk. WFDC2 may help refine stroke risk stratification in individuals with CKD.
- Open Access
- 20 September 2026
- Published by MDPI AG in Antioxidants
- Vol. 15 (9) , 1205
Shengmai Yin Attenuates Hypobaric Hypoxia-Induced Erythrocyte Echinocytosis by Restoring Redox Homeostasis and Normalizing Band 3–Syk/SHP2 Interactions
Acute exposure to high-altitude hypobaric hypoxia (HH) disrupts redox homeostasis and impairs erythrocyte morphology and oxygen transport. Shengmai Yin (SMY) is a botanical formulation with reported antioxidant activity, but its effects on HH-induced erythrocyte injury remain unclear. Male C57BL/6J mice received SMY in drinking water for 3 days before 24 h of simulated HH equivalent to 6000 m. Complementary in vivo and in vitro experiments assessed redox indices, lipid peroxidation, hemoglobin redox status, erythrocyte morphology, arterial oxygenation, and Band 3-associated protein interactions. HH increased serum DHE-derived fluorescence, nitric oxide, and malondialdehyde, reduced antioxidant capacity, induced echinocytosis, decreased oxyhemoglobin, and increased methemoglobin. Among the tested redox challenges, 2-phenyl-4,4,5,5-tetramethylimidazoline-1-oxyl 3-oxide (PTIO) most closely reproduced the combined morphological and hemoglobin abnormalities. SMY scavenged DPPH, hydroxyl-radical, and superoxide-related signals in cell-free assays; reduced PTIO- and hypoxia-induced erythrocyte damage; and reversed established echinocytosis within 30 min in vitro. In mice, SMY reduced echinocytosis and improved arterial oxygenation without detectable short-term hepatic, renal, or histological toxicity. SMY also normalized HH- and PTIO-induced changes in Band 3 interactions with Syk and SHP2. These findings support SMY as a redox-modulating intervention that preserves erythrocyte structure and function during acute HH.
- 20 September 2026
- Published by MDPI AG in Antioxidants
- Vol. 15 (9) , 1205
Open AccessShengmai Yin Attenuates Hypobaric Hypoxia-Induced Erythrocyte Echinocytosis by Restoring Redox Homeostasis and Normalizing Band 3–Syk/SHP2 Interactions
Acute exposure to high-altitude hypobaric hypoxia (HH) disrupts redox homeostasis and impairs erythrocyte morphology and oxygen transport. Shengmai Yin (SMY) is a botanical formulation with reported antioxidant activity, but its effects on HH-induced erythrocyte injury remain unclear. Male C57BL/6J mice received SMY in drinking water for 3 days before 24 h of simulated HH equivalent to 6000 m. Complementary in vivo and in vitro experiments assessed redox indices, lipid peroxidation, hemoglobin redox status, erythrocyte morphology, arterial oxygenation, and Band 3-associated protein interactions. HH increased serum DHE-derived fluorescence, nitric oxide, and malondialdehyde, reduced antioxidant capacity, induced echinocytosis, decreased oxyhemoglobin, and increased methemoglobin. Among the tested redox challenges, 2-phenyl-4,4,5,5-tetramethylimidazoline-1-oxyl 3-oxide (PTIO) most closely reproduced the combined morphological and hemoglobin abnormalities. SMY scavenged DPPH, hydroxyl-radical, and superoxide-related signals in cell-free assays; reduced PTIO- and hypoxia-induced erythrocyte damage; and reversed established echinocytosis within 30 min in vitro. In mice, SMY reduced echinocytosis and improved arterial oxygenation without detectable short-term hepatic, renal, or histological toxicity. SMY also normalized HH- and PTIO-induced changes in Band 3 interactions with Syk and SHP2. These findings support SMY as a redox-modulating intervention that preserves erythrocyte structure and function during acute HH.
- Open Access
- 29 July 2026
- Published by Wiley in CNS Neuroscience & Therapeutics
- Vol. 32 (8) , e71059
Accelerated Biological Aging, Neurodegenerative Disease, and Mortality in Cardiovascular Disease Patients: Mediation and Modification Analysis
Aims: Cardiovascular disease (CVD) patients exhibit increased neurodegenerative diseases and mortality risks, implying a shared heart‐brain aging pathway. As a composite biological aging predictor, the association of Phenotypic age (PhenoAge) with mortality and the mediating role of brain health remain unclear in CVD patients. Methods: In 4104 CVD patients (57.3% male, mean age 67.3 years) from the National Health and Nutrition Examination Survey (median follow‐up of 7.2 years), weighted regression models examined associations of PhenoAge and its acceleration with Alzheimer's disease (AD), Parkinson's disease (PD), and mortality. Mediation effects of the association between PhenoAge and mortality explained by AD and PD were quantified. Results: The mean PhenoAge was 69.9 years, and AD and PD prevalences were 7.6% and 1.8%. Each 5‐year increment of PhenoAge acceleration independently increased risks of AD (OR = 1.24; 95% CI:1.13,1.36), PD (OR = 1.22; 95% CI:1.02,1.46), and all‐cause mortality (HR = 1.30; 95% CI:1.24,1.36). AD and PD mediated 20.46%–33.18% of the association between PhenoAge and mortality. Early‐onset CVD amplified biological aging‐related mortality risk, while a healthier lifestyle attenuated the CVD mortality risk ( P interaction < 0.05). Conclusion: Accelerated biological aging was associated with adverse brain health outcomes and mortality in CVD patients, with AD and PD as significant mediators. PhenoAge assessment may identify high‐risk individuals for personalized heart‐brain aging prevention.
- 29 July 2026
- Published by Wiley in CNS Neuroscience & Therapeutics
- Vol. 32 (8) , e71059
Open AccessAccelerated Biological Aging, Neurodegenerative Disease, and Mortality in Cardiovascular Disease Patients: Mediation and Modification Analysis
Aims: Cardiovascular disease (CVD) patients exhibit increased neurodegenerative diseases and mortality risks, implying a shared heart‐brain aging pathway. As a composite biological aging predictor, the association of Phenotypic age (PhenoAge) with mortality and the mediating role of brain health remain unclear in CVD patients. Methods: In 4104 CVD patients (57.3% male, mean age 67.3 years) from the National Health and Nutrition Examination Survey (median follow‐up of 7.2 years), weighted regression models examined associations of PhenoAge and its acceleration with Alzheimer's disease (AD), Parkinson's disease (PD), and mortality. Mediation effects of the association between PhenoAge and mortality explained by AD and PD were quantified. Results: The mean PhenoAge was 69.9 years, and AD and PD prevalences were 7.6% and 1.8%. Each 5‐year increment of PhenoAge acceleration independently increased risks of AD (OR = 1.24; 95% CI:1.13,1.36), PD (OR = 1.22; 95% CI:1.02,1.46), and all‐cause mortality (HR = 1.30; 95% CI:1.24,1.36). AD and PD mediated 20.46%–33.18% of the association between PhenoAge and mortality. Early‐onset CVD amplified biological aging‐related mortality risk, while a healthier lifestyle attenuated the CVD mortality risk ( P interaction < 0.05). Conclusion: Accelerated biological aging was associated with adverse brain health outcomes and mortality in CVD patients, with AD and PD as significant mediators. PhenoAge assessment may identify high‐risk individuals for personalized heart‐brain aging prevention.
- Open Access
- 9 July 2026
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 24 (1)
Melatonin promotes recovery from ischemic stroke by modulating microglia polarization and inhibiting oligodendrocyte pyroptosis via the RORα/AMPKα/STAT1 pathway
This study investigates how melatonin affects white matter damage and oligodendrocyte pyroptosis after ischemic stroke by modulating microglia polarization
- 9 July 2026
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 24 (1)
Open AccessMelatonin promotes recovery from ischemic stroke by modulating microglia polarization and inhibiting oligodendrocyte pyroptosis via the RORα/AMPKα/STAT1 pathway
This study investigates how melatonin affects white matter damage and oligodendrocyte pyroptosis after ischemic stroke by modulating microglia polarization
- Open Access
- 9 July 2026
- Published by Springer Nature in Cell Death Discovery
- Vol. 12 (1)
LINC01929 promotes breast cancer progression through a TFRC-associated ferroptosis pathway
Breast cancer (BC) remains the most prevalent malignancy among women worldwide, with persistent challenges such as drug resistance and tumor progression despite significant therapeutic advancements. The roles of ferroptosis and long non-coding RNAs (lncRNAs) in BC are not yet fully elucidated, underscoring the need for novel therapeutic targets. In this study, we investigated the function of LINC01929 in BC through a combination of in vitro and in vivo experiments, bioinformatics analysis, RNA pull-down mass spectrometry, and clinical tissue validation. We found that LINC01929 is significantly overexpressed in BC tissues and is associated with poor patient prognosis. Mechanistically, LINC01929 promoted malignant phenotypes in BC cells and was associated with reduced ferroptosis-related stress, with these effects being at least partly dependent on transferrin receptor (TFRC). Conversely, silencing LINC01929 led to reduced TFRC expression and induced ferroptosis in BC cells. Clinical data further confirmed that elevated TFRC levels correlate with aggressive tumor features and unfavorable outcomes. These findings suggest that targeting LINC01929 to regulate TFRC-mediated ferroptosis could represent a promising therapeutic strategy for BC, positioning both LINC01929 and TFRC as potential biomarkers and therapeutic targets.
- 9 July 2026
- Published by Springer Nature in Cell Death Discovery
- Vol. 12 (1)
Open AccessLINC01929 promotes breast cancer progression through a TFRC-associated ferroptosis pathway
Breast cancer (BC) remains the most prevalent malignancy among women worldwide, with persistent challenges such as drug resistance and tumor progression despite significant therapeutic advancements. The roles of ferroptosis and long non-coding RNAs (lncRNAs) in BC are not yet fully elucidated, underscoring the need for novel therapeutic targets. In this study, we investigated the function of LINC01929 in BC through a combination of in vitro and in vivo experiments, bioinformatics analysis, RNA pull-down mass spectrometry, and clinical tissue validation. We found that LINC01929 is significantly overexpressed in BC tissues and is associated with poor patient prognosis. Mechanistically, LINC01929 promoted malignant phenotypes in BC cells and was associated with reduced ferroptosis-related stress, with these effects being at least partly dependent on transferrin receptor (TFRC). Conversely, silencing LINC01929 led to reduced TFRC expression and induced ferroptosis in BC cells. Clinical data further confirmed that elevated TFRC levels correlate with aggressive tumor features and unfavorable outcomes. These findings suggest that targeting LINC01929 to regulate TFRC-mediated ferroptosis could represent a promising therapeutic strategy for BC, positioning both LINC01929 and TFRC as potential biomarkers and therapeutic targets.
- Open Access
- 5 May 2026
- Published by Spandidos Publications in International Journal of Molecular Medicine
- Vol. 58 (1) , 1-20
Ferroptosis in musculoskeletal disorders: Emerging mechanisms and therapeutic opportunities (Review)
Ferroptosis, an iron‑dependent form of regulated cell death driven by lipid peroxidation, has emerged as a key mechanism underlying tissue degeneration and impaired regeneration in musculoskeletal disorders. Although ferroptosis is associated with conditions such as tendinopathy, sarcopenia, osteoarthritis and osteoporosis, systematic synthesis connecting molecular mechanisms with disease‑specific contexts and translational implications remains limited. The present review summarizes the fundamental molecular mechanisms of ferroptosis, including iron metabolism dysregulation, lipid peroxidation processes and antioxidant defense systems centered on GPX4 and glutathione. Subsequently, the involvement of ferroptosis across major musculoskeletal diseases was investigated, highlighting how iron imbalance, oxidative stress and age‑related alterations collectively contribute to tissue dysfunction and degeneration. Particular emphasis is placed on aging‑associated changes in iron homeostasis and antioxidant capacity as potential amplifiers of ferroptotic vulnerability in musculoskeletal tissues. Experimental modeling strategies and pharmacological modulation approaches used to investigate ferroptosis in musculoskeletal research are further discussed and their mechanistic relevance and translational challenges are analyzed. Finally, the present review outlines emerging therapeutic perspectives and future research directions aimed at improving the understanding and potential clinical targeting of ferroptosis in musculoskeletal disorders. By providing a structured and integrative synthesis, the present review clarifies the role of ferroptosis at the intersection of iron dysregulation, redox imbalance and musculoskeletal decline.
- 5 May 2026
- Published by Spandidos Publications in International Journal of Molecular Medicine
- Vol. 58 (1) , 1-20
Open AccessFerroptosis in musculoskeletal disorders: Emerging mechanisms and therapeutic opportunities (Review)
Ferroptosis, an iron‑dependent form of regulated cell death driven by lipid peroxidation, has emerged as a key mechanism underlying tissue degeneration and impaired regeneration in musculoskeletal disorders. Although ferroptosis is associated with conditions such as tendinopathy, sarcopenia, osteoarthritis and osteoporosis, systematic synthesis connecting molecular mechanisms with disease‑specific contexts and translational implications remains limited. The present review summarizes the fundamental molecular mechanisms of ferroptosis, including iron metabolism dysregulation, lipid peroxidation processes and antioxidant defense systems centered on GPX4 and glutathione. Subsequently, the involvement of ferroptosis across major musculoskeletal diseases was investigated, highlighting how iron imbalance, oxidative stress and age‑related alterations collectively contribute to tissue dysfunction and degeneration. Particular emphasis is placed on aging‑associated changes in iron homeostasis and antioxidant capacity as potential amplifiers of ferroptotic vulnerability in musculoskeletal tissues. Experimental modeling strategies and pharmacological modulation approaches used to investigate ferroptosis in musculoskeletal research are further discussed and their mechanistic relevance and translational challenges are analyzed. Finally, the present review outlines emerging therapeutic perspectives and future research directions aimed at improving the understanding and potential clinical targeting of ferroptosis in musculoskeletal disorders. By providing a structured and integrative synthesis, the present review clarifies the role of ferroptosis at the intersection of iron dysregulation, redox imbalance and musculoskeletal decline.
- Open Access
- 1 February 2026
- Published by SAGE Publications in Digital Health
- Vol. 12
Predicting health-related quality of life in patients with cancer using machine learning: A step toward personalized oncology care
Objective: With the increasing global burden of cancer, there is a growing need for innovative strategies to improve oncology care. Health-related quality of life (HRQoL) is an outcome measure for assessing the overall wellbeing of patients with cancer. We used machine learning to predict HRQoL and to identify key factors that can inform patient-centered cancer care. Methods: We conducted a cross-sectional study enrolling patients diagnosed with lung, breast, or colorectal cancer across two provinces in China. We collected data on demographics, clinical characteristics, and patient-centered features. HRQoL was assessed using the widely accepted EQ-5D-5L instrument in cancer care. We trained and evaluated seven machine learning models. SHapley Additive exPlanations (SHAP) analysis was employed to assess feature importance. Results: Data from 924 patients with cancer were available. The random forest and extreme gradient boosting models had superior predictive performance. Positive SHAP values were primarily observed in patients with early-stage cancer and those enrolled in Urban Employees Basic Medical Insurance. Negative SHAP values were mainly associated with longer duration of chronic comorbidities, colorectal cancer, and ongoing chemotherapy. Age and time since cancer diagnosis exhibited bidirectional impacts. Conclusions: Our study demonstrates the potential of machine learning models to predict HRQoL in patients with cancer. We identified key predictors of patient HRQoL, like duration of chronic comorbidities, early-stage cancer diagnosis, age, and health insurance coverage. Our findings would facilitate early identification of patients with lower HRQoL and promote the provision of patient-centered oncology care.
- 1 February 2026
- Published by SAGE Publications in Digital Health
- Vol. 12
Open AccessPredicting health-related quality of life in patients with cancer using machine learning: A step toward personalized oncology care
Objective: With the increasing global burden of cancer, there is a growing need for innovative strategies to improve oncology care. Health-related quality of life (HRQoL) is an outcome measure for assessing the overall wellbeing of patients with cancer. We used machine learning to predict HRQoL and to identify key factors that can inform patient-centered cancer care. Methods: We conducted a cross-sectional study enrolling patients diagnosed with lung, breast, or colorectal cancer across two provinces in China. We collected data on demographics, clinical characteristics, and patient-centered features. HRQoL was assessed using the widely accepted EQ-5D-5L instrument in cancer care. We trained and evaluated seven machine learning models. SHapley Additive exPlanations (SHAP) analysis was employed to assess feature importance. Results: Data from 924 patients with cancer were available. The random forest and extreme gradient boosting models had superior predictive performance. Positive SHAP values were primarily observed in patients with early-stage cancer and those enrolled in Urban Employees Basic Medical Insurance. Negative SHAP values were mainly associated with longer duration of chronic comorbidities, colorectal cancer, and ongoing chemotherapy. Age and time since cancer diagnosis exhibited bidirectional impacts. Conclusions: Our study demonstrates the potential of machine learning models to predict HRQoL in patients with cancer. We identified key predictors of patient HRQoL, like duration of chronic comorbidities, early-stage cancer diagnosis, age, and health insurance coverage. Our findings would facilitate early identification of patients with lower HRQoL and promote the provision of patient-centered oncology care.
- Open Access
- 9 September 2025
- Published by Elsevier in Journal of Advanced Research
- Vol. 84, 235-255
Targeting CIRP and IL-6R-mediated microglial inflammation to improve outcomes in intracerebral hemorrhage
- 9 September 2025
- Published by Elsevier in Journal of Advanced Research
- Vol. 84, 235-255
Open AccessTargeting CIRP and IL-6R-mediated microglial inflammation to improve outcomes in intracerebral hemorrhage
- Open Access
- 8 June 2025
- Published by Wiley in CNS Neuroscience & Therapeutics
- Vol. 31 (6) , e70471
Targeting HDAC3 Suppresses Ferroptosis and Demyelination in White Matter Injury by Restoring PDK4‐Mediated Iron Homeostasis
Aim: White matter injury (WMI), characterized by white matter degeneration and iron deposition, contributes to neurological dysfunction. Histone deacetylase 3 (HDAC3) is implicated in neurodegenerative processes, yet its role in WMI‐associated ferroptosis remains unclear.Methods: Clinical assessments in WMI patients revealed correlations between serum iron, α‐synuclein, and antioxidant levels and MRI‐confirmed white matter degeneration. In a cuprizone‐induced demyelination mouse model, white matter integrity, oligodendrocyte dysfunction, iron accumulation, and lipid peroxidation were evaluated through behavioral testing, histological staining, and biochemical analyses. To identify potential molecular targets of HDAC3‐mediated ferroptosis, CUT&Tag sequencing was performed. The involvement of this pathway was further validated in vitro using iron overload assays and in vivo through HDAC3 overexpression via AAV vectors.Results: In the present study, HDAC3 expression was elevated following demyelination and was suppressed by RGFP966 treatment. Brain MRI findings from clinical patients and histological analyses in CPZ‐treated mice revealed disrupted iron metabolism following white matter injury, likely driven by increased iron deposition and lipid peroxidation in the affected regions. HDAC3 inhibition alleviated oligodendrocyte lineage dysfunction, preserved myelin integrity, and mitigated cognitive and motor deficits induced by demyelination. CUT&Tag sequencing suggested that the therapeutic effects of RGFP966 are mediated through HDAC3‐dependent regulation of ferroptosis. The reliability of these findings was further supported by in vivo validation of ferroptosis‐related gene expression, indicating that the HDAC3–pyruvate dehydrogenase kinase 4 (PDK4) axis plays a critical role in the epigenetic regulation of ferroptosis‐related pathways.Conclusion: HDAC3 drives ferroptosis in WMI via iron metabolism and lipid peroxidation, highlighting the HDAC3‐PDK4 axis as a therapeutic target.
- 8 June 2025
- Published by Wiley in CNS Neuroscience & Therapeutics
- Vol. 31 (6) , e70471
Open AccessTargeting HDAC3 Suppresses Ferroptosis and Demyelination in White Matter Injury by Restoring PDK4‐Mediated Iron Homeostasis
Aim: White matter injury (WMI), characterized by white matter degeneration and iron deposition, contributes to neurological dysfunction. Histone deacetylase 3 (HDAC3) is implicated in neurodegenerative processes, yet its role in WMI‐associated ferroptosis remains unclear.Methods: Clinical assessments in WMI patients revealed correlations between serum iron, α‐synuclein, and antioxidant levels and MRI‐confirmed white matter degeneration. In a cuprizone‐induced demyelination mouse model, white matter integrity, oligodendrocyte dysfunction, iron accumulation, and lipid peroxidation were evaluated through behavioral testing, histological staining, and biochemical analyses. To identify potential molecular targets of HDAC3‐mediated ferroptosis, CUT&Tag sequencing was performed. The involvement of this pathway was further validated in vitro using iron overload assays and in vivo through HDAC3 overexpression via AAV vectors.Results: In the present study, HDAC3 expression was elevated following demyelination and was suppressed by RGFP966 treatment. Brain MRI findings from clinical patients and histological analyses in CPZ‐treated mice revealed disrupted iron metabolism following white matter injury, likely driven by increased iron deposition and lipid peroxidation in the affected regions. HDAC3 inhibition alleviated oligodendrocyte lineage dysfunction, preserved myelin integrity, and mitigated cognitive and motor deficits induced by demyelination. CUT&Tag sequencing suggested that the therapeutic effects of RGFP966 are mediated through HDAC3‐dependent regulation of ferroptosis. The reliability of these findings was further supported by in vivo validation of ferroptosis‐related gene expression, indicating that the HDAC3–pyruvate dehydrogenase kinase 4 (PDK4) axis plays a critical role in the epigenetic regulation of ferroptosis‐related pathways.Conclusion: HDAC3 drives ferroptosis in WMI via iron metabolism and lipid peroxidation, highlighting the HDAC3‐PDK4 axis as a therapeutic target.